BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Berenberg analyst Harry Gillis raised the firm’s price target on BioNTech (BNTX) to $155 from $150 and keeps a Buy rating on the shares. Published ...

BioNTech's latest narrative update reflects a slightly higher fair value estimate of about $138, tempered by a modestly increased discount rate of roughly 6.72%, as analysts balance confidence in the ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

Despite these strategic and clinical developments, BioNTech's share price has faced pressure recently, down approximately 15% over the past 30 days and roughly 27% year-to-date. The stock trades more ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to ...

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as ...

BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status. Sahin received a pay package worth 11.59 ...